riviciclib

Generic Name: riviciclib

Clinical Trials

A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00

Phase 2

Completed

Conditions: Radiation Induced Mucositis in Head and Neck Cancer

Interventions: Drug: P276-00
Radiation: Radiation Therapy
Drug: Cisplatin

First Posted Date: 2013-07-19

Last Posted Date: 2014-09-04

Lead Sponsor: Piramal Enterprises Limited

Target Recruit Count: 73

Registration Number: NCT01903018

Locations: 🇮🇳
Sri Venkateshwara Hospitals, Bangalore, Karnataka, India
🇮🇳
Meenakshi Mission Hosp. & Res. Centre, Madurai, Tamil Nadu, India
🇮🇳
Tata Memorial Hospital, Mumbai, Maharashtra, India

and more 4 locations

Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: P276-00
Radiation: External beam radiotherapy (EBRT)

First Posted Date: 2009-05-12

Last Posted Date: 2012-11-22

Lead Sponsor: Piramal Enterprises Limited

Target Recruit Count: 23

Registration Number: NCT00899054

Locations: 🇮🇳
Bhagwan Mahawir Cancer Hospital & Research Centre, Jaipur, Rajasthan, India
🇮🇳
Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India
🇮🇳
Curie Manavata Cancer Center, Nashik, Maharashtra, India

and more 3 locations

Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: P276-00
Drug: Gemcitabine

First Posted Date: 2009-05-12

Last Posted Date: 2012-01-20

Lead Sponsor: Piramal Enterprises Limited

Target Recruit Count: 23

Registration Number: NCT00898287

Locations: 🇮🇳
Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, India
🇮🇳
Global Hospital, Hyderabaad, Andhra Pradesh, India
🇮🇳
Curie Manavata Cancer Centre, Nashik, Maharashtra, India

and more 4 locations

Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Drug: P276-00

First Posted Date: 2009-04-16

Last Posted Date: 2012-11-21

Lead Sponsor: Piramal Enterprises Limited

Target Recruit Count: 19

Registration Number: NCT00882063

Locations: 🇮🇳
Shatabdi Superspeciality Hospital, Nasik, Maharashtra, India
🇮🇳
Jaslok Hospital & Research Centre, Mumbai, Maharashtra, India
🇮🇳
Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata, West Bengal, India

and more 2 locations

A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma

Phase 2

Terminated

Conditions: Mantle Cell Lymphoma

Interventions: Drug: P276-00

First Posted Date: 2009-02-13

Last Posted Date: 2012-07-27

Lead Sponsor: Piramal Enterprises Limited

Target Recruit Count: 13

Registration Number: NCT00843050

Locations: 🇺🇸
Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Arizona, Scottsdale, Arizona, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇮🇳
Malabar Institute of Medical Sciences, Calicut, Kerala, India

and more 15 locations

Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: P276-00

First Posted Date: 2009-02-03

Last Posted Date: 2012-12-04

Lead Sponsor: Piramal Enterprises Limited

Target Recruit Count: 12

Registration Number: NCT00835419

Locations: 🇮🇳
Curie Manavata Cancer Center, Nasik, Maharashtra, India
🇳🇿
Christchurch Oncology Research Unit, Oncology Service, Christchurch Hospital, Riccarton Avenue, Private Bag 4710, Christchurch,, Christchurch, New Zealand
🇦🇺
John Fawkner Cancer Trial Centre, Victoria, Australia

and more 4 locations

A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: P276-00

First Posted Date: 2009-01-16

Last Posted Date: 2013-07-10

Lead Sponsor: Piramal Enterprises Limited

Target Recruit Count: 86

Registration Number: NCT00824343

Locations: 🇮🇳
Bhagwan Mahaveer Cancer Hospital & Research Centre, Dept. Of Medical Oncology, Jaipur, Jaipur, Rajasthan, India
🇮🇳
Bharath Hospital & Institute of Oncology, Mysore, Mysore, Karnataka, India
🇮🇳
Regional Cancer Centre, Trivandrum, Kerala, India

and more 6 locations

Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma

Phase 1

Withdrawn

Conditions: Multiple Myeloma

First Posted Date: 2007-10-22

Last Posted Date: 2009-04-23

Lead Sponsor: Piramal Enterprises Limited

Target Recruit Count: 35

Registration Number: NCT00547404

Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms

Phase 1

Terminated

Conditions: Neoplasm

First Posted Date: 2006-12-05

Last Posted Date: 2009-01-01

Lead Sponsor: Piramal Enterprises Limited

Target Recruit Count: 28

Registration Number: NCT00408018

Locations: 🇮🇳
Nizam's Institute of Medicai Sciences, Hyderabaad, Andhra Pradesh, India
🇮🇳
Global Hospital, Hyderabad, Andhra Pradesh, India
🇮🇳
Tata Memorial Hospital, Mumbai, Maharashtra, India

Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms

Phase 1

Completed

Conditions: Neoplasm

First Posted Date: 2006-12-05

Last Posted Date: 2009-01-01

Lead Sponsor: Piramal Enterprises Limited

Target Recruit Count: 50

Registration Number: NCT00407498

Locations: 🇨🇦
Juravinsky Cancer Centre, Hamilton, Ontario, Canada
🇮🇳
Nizam's Institute of Medicai Sciences, Hyderabaad, Andhrapradesh, India
🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy